# Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

> **NCT06042569** · PHASE2 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 174 (estimated)

## Conditions studied

- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- HER2-Negative Breast Carcinoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel
- **OTHER:** Medical Chart Review
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06042569
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-16
- **Primary completion:** 2030-03-20
- **Final completion:** 2030-03-20
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06042569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06042569, "Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06042569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*